0000950170-24-010975.txt : 20240202 0000950170-24-010975.hdr.sgml : 20240202 20240202213512 ACCESSION NUMBER: 0000950170-24-010975 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240201 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Savill Corrine CENTRAL INDEX KEY: 0001837524 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 24593713 MAIL ADDRESS: STREET 1: C/O CULLINAN ONCOLOGY, LLC STREET 2: ONE MAIN STREET SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cullinan Oncology, Inc. CENTRAL INDEX KEY: 0001789972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813867811 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 1350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-410-4650 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 1350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Management, Inc. DATE OF NAME CHANGE: 20210107 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, LLC DATE OF NAME CHANGE: 20191001 4 1 ownership.xml 4 X0508 4 2024-02-01 0001789972 Cullinan Oncology, Inc. CGEM 0001837524 Savill Corrine C/O CULLINAN ONCOLOGY, INC. ONE MAIN STREET, SUITE 1350 CAMBRIDGE MA 02142 false true false false Chief Business Officer true Common Stock 2024-02-01 4 M false 40000 4.30 A 205990 D Common Stock 2024-02-01 4 S false 40000 16.18 D 165990 D Stock Option (Right to Buy) 4.3 2024-02-01 4 M false 40000 0 D 2030-10-31 Common Stock 40000 70331 D Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.52. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the shares vested on September 1, 2019, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on September 1, 2022. /s/ Jacquelyn Sumer, Attorney-in-Fact 2024-02-02